menu
    • menu
    [{"orgOrder":0,"company":"Medreg","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MRG-001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Medreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medreg \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medreg \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Caspofungin","moa":"1,3-beta-glucan synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Merck & Co"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Beike Bio-Technology Co., Ltd.","sponsor":"The Second Affiliated Hospital of Kunming Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Beike Bio-Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Beike Bio-Technology Co., Ltd. \/ The Second Affiliated Hospital of Kunming Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Beike Bio-Technology Co., Ltd. \/ The Second Affiliated Hospital of Kunming Medical University"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Spaulding Rehabilitation Hospital | Albert Einstein Healthcare Network | Indiana University | Craig Hospital | TIRR Memorial Hermann","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Baylor College of Medicine \/ Spaulding Rehabilitation Hospital | Albert Einstein Healthcare Network | Indiana University | Craig Hospital | TIRR Memorial Hermann","highestDevelopmentStatusID":"10","companyTruncated":"Baylor College of Medicine \/ Spaulding Rehabilitation Hospital | Albert Einstein Healthcare Network | Indiana University | Craig Hospital | TIRR Memorial Hermann"},{"orgOrder":0,"company":"Catholic University of Korea Saint Paul's Hospital","sponsor":"National Health Insurance Service Ilsan Hospital | Medy-Tox","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Catholic University of Korea Saint Paul's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catholic University of Korea Saint Paul's Hospital \/ National Health Insurance Service Ilsan Hospital | Medy-Tox","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea Saint Paul's Hospital \/ National Health Insurance Service Ilsan Hospital | Medy-Tox"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Bordeaux \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Bordeaux \/ Ipsen"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"AMRMC","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Cognition \/ AMRMC","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ AMRMC"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Walter Reed Army Institute","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Walter Reed Army Institute","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Walter Reed Army Institute"},{"orgOrder":0,"company":"University of Virginia School of Medicine","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"University of Virginia School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia School of Medicine \/ Adial Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Virginia School of Medicine \/ Adial Pharmaceuticals"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Bronx VA Medical Center","sponsor":"Chelsea Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Bronx VA Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bronx VA Medical Center \/ Chelsea Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Bronx VA Medical Center \/ Chelsea Therapeutics"},{"orgOrder":0,"company":"ProCertus BioPharm","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Norepinephrine","moa":"Adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"ProCertus BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"ProCertus BioPharm \/ Moffitt Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"ProCertus BioPharm \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"ProCertus BioPharm","sponsor":"University of Wisconsin, Madison","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Norepinephrine","moa":"Adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"ProCertus BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"ProCertus BioPharm \/ University of Wisconsin, Madison","highestDevelopmentStatusID":"7","companyTruncated":"ProCertus BioPharm \/ University of Wisconsin, Madison"},{"orgOrder":0,"company":"Carilion Clinic","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Carilion Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carilion Clinic \/ Provepharm Life Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Carilion Clinic \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Omeros","amount2":1,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":1,"dosageForm":"Solution","sponsorNew":"Omeros \/ Rayner Surgical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner Surgical Group Limited"},{"orgOrder":0,"company":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","sponsor":"Canadian Critical Care Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal \/ Canadian Critical Care Trials Group","highestDevelopmentStatusID":"9","companyTruncated":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal \/ Canadian Critical Care Trials Group"},{"orgOrder":0,"company":"Xinchen Wang","sponsor":"Tibet Autonomous Region People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Xinchen Wang","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xinchen Wang \/ Tibet Autonomous Region People\u2019s Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Xinchen Wang \/ Tibet Autonomous Region People\u2019s Hospital"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jeffrey Alan Klein","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Jeffrey Alan Klein","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jeffrey Alan Klein \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jeffrey Alan Klein \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Albumin","moa":"Albumin||Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shilpa Medicare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shilpa Medicare \/ Undisclosed"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Recombinant Human Albumin","moa":"Albumin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shilpa Medicare \/ Orion Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Shilpa Medicare \/ Orion Corporation"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Public Offering","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Private Placement","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"University of Zurich","sponsor":"Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Alanyl Glutamine","moa":"Amino acid metabolism","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Zurich \/ Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich","highestDevelopmentStatusID":"11","companyTruncated":"University of Zurich \/ Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"Shanghai Meiji Health Science and Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Shanghai Meiji Health Science and Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Meiji Health Science and Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Meiji Health Science and Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"The Dana Foundation | Main Line Health | University of Pennsylvania | Pennsylvania Department of Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Children's Hospital of Philadelphia \/ The Dana Foundation | Main Line Health | University of Pennsylvania | Pennsylvania Department of Health","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ The Dana Foundation | Main Line Health | University of Pennsylvania | Pennsylvania Department of Health"},{"orgOrder":0,"company":"Synlogic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SYNB1020","moa":"Ammonia","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synlogic \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Synlogic \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"US Department of Defense | Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxandrolone","moa":"Androgen Receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ US Department of Defense | Walter Reed National Military Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ US Department of Defense | Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"North Florida Foundation for Research and Education","sponsor":"North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"Androgen Receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"North Florida Foundation for Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"North Florida Foundation for Research and Education \/ North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"North Florida Foundation for Research and Education \/ North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tedelparin","moa":"Antithrombin-III","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"BILIX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BX-001N","moa":"Bacteria microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BILIX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BILIX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BILIX \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Neomycin","moa":"Bacterial 70S ribosome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"SIFI","sponsor":"Sintesi Research Srl","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Netilmicin","moa":"Bacterial 70S ribosome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"SIFI \/ Sintesi Research Srl","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Sintesi Research Srl"},{"orgOrder":0,"company":"NanoSHIFT","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase 13 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"NanoSHIFT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"NanoSHIFT \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"NanoSHIFT \/ US Department of Defense"},{"orgOrder":0,"company":"NanoSHIFT","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase 13 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"NanoSHIFT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"NanoSHIFT \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"NanoSHIFT \/ US Department of Defense"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"NanoSHIFT","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase 13 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Massachusetts General Hospital \/ NanoSHIFT","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ NanoSHIFT"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Benzalkonium Chloride","moa":"Bacterial cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Loma Linda University","sponsor":"Irrimax Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Irrisept","moa":"Bacterial cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Loma Linda University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Loma Linda University \/ Irrimax Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Loma Linda University \/ Irrimax Corporation"},{"orgOrder":0,"company":"Xinnate","sponsor":"Region Skane","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TCP-25","moa":"Bacterial cell wall","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Xinnate","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xinnate \/ Region Skane","highestDevelopmentStatusID":"6","companyTruncated":"Xinnate \/ Region Skane"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Bausch Health"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"Alfasigma | LC2 Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ Alfasigma | LC2 Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ Alfasigma | LC2 Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Texas Tech University Health Sciences Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Texas Tech University Health Sciences Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University Health Sciences Center \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Texas Tech University Health Sciences Center \/ Merck & Co"},{"orgOrder":0,"company":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","sponsor":"Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children\u2019s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dobutamine Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz \/ Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children\u2019s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni","highestDevelopmentStatusID":"7","companyTruncated":"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz \/ Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children\u2019s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Central Hospital, Nancy, France \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Central Hospital, Nancy, France \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intermountain Health \/ Beth Israel Deaconess Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Intermountain Health \/ Beth Israel Deaconess Medical Center"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"QATAR","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"London Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"German Research Foundation | Grifols International | University Hospital G\u00f6ttingen | SepNet - Critical Care Trials Group | Center for Sepsis Control and Care, Germany","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ German Research Foundation | Grifols International | University Hospital G\u00f6ttingen | SepNet - Critical Care Trials Group | Center for Sepsis Control and Care, Germany","highestDevelopmentStatusID":"10","companyTruncated":"Jena University Hospital \/ German Research Foundation | Grifols International | University Hospital G\u00f6ttingen | SepNet - Critical Care Trials Group | Center for Sepsis Control and Care, Germany"},{"orgOrder":0,"company":"Hunter Holmes Mcguire Veteran Affairs Medical Center","sponsor":"Grifols International | McGuire Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Hunter Holmes Mcguire Veteran Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ Grifols International | McGuire Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ Grifols International | McGuire Research Institute"},{"orgOrder":0,"company":"Hunter Holmes Mcguire Veteran Affairs Medical Center","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Hunter Holmes Mcguire Veteran Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ Grifols International"},{"orgOrder":0,"company":"Anahita Rabiee MD MHS","sponsor":"Grifols Shared Services North America Inc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Anahita Rabiee MD MHS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anahita Rabiee MD MHS \/ Grifols Shared Services North America Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anahita Rabiee MD MHS \/ Grifols Shared Services North America Inc"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Albimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Albumin","moa":"Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Albimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Albimmune \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institutes of Health"},{"orgOrder":0,"company":"Pluri","sponsor":"Hemafund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Hemafund","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Hemafund"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institutes of Health"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Healthpoint","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Bacitracin Zinc","moa":"C55-isoprenyl pyrophosphate","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Louisville \/ Healthpoint","highestDevelopmentStatusID":"11","companyTruncated":"University of Louisville \/ Healthpoint"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BLD-2660","moa":"Calpain","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BLD-2660","moa":"Calpain","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Incannex Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Incannex Healthcare"},{"orgOrder":0,"company":"HempMeds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HempMeds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oil","sponsorNew":"HempMeds \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"HempMeds \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Curia","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Curia","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Curia"},{"orgOrder":0,"company":"CommonSpirit Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"CommonSpirit Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CommonSpirit Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CommonSpirit Health \/ Undisclosed"},{"orgOrder":0,"company":"Barth Wilsey","sponsor":"VA Northern California Health Care System | University of California, San Diego | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Cannabis","moa":"Cannabinoid receptor 1; Cannabinoid receptor 2; G-protein coupled receptor 12; Glycine receptor subunit alpha-1; Glycine receptor (alpha-1\/beta); Glycine receptor subunit alpha-3; N-arachidonyl glycine receptor; G-protein coupled receptor 55; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Neuronal acetylcholine receptor subunit alpha-7; Delta-type opioid receptor; Mu-type opioid receptor; Peroxisome proliferator-activated receptor gamma; Transient receptor potential cation channel subfamily V member 1; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Transient receptor potential cation channel subfamily A member 1; Transient receptor potential cation channel subfamily M member 8; Transient receptor potential cation channel subfamily V member 2; Transient receptor potential cation channel subfamily V member 3; Transient receptor potential cat","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Barth Wilsey","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barth Wilsey \/ VA Northern California Health Care System | University of California, San Diego | National Institute on Drug Abuse","highestDevelopmentStatusID":"9","companyTruncated":"Barth Wilsey \/ VA Northern California Health Care System | University of California, San Diego | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Emricasan","moa":"Caspase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Megalabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"L-Arginine","moa":"Cationic amino acid transporter 3; Antizyme inhibitor 2; Argininosuccinate lyase; Nitric oxide synthase, inducible; High affinity cationic amino acid transporter 1; Arginase-2, mitochondrial; Cationic amino acid transporter 4; Argininosuccinate synthase; Nitric oxide synthase 3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalabs \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Megalabs \/ Undisclosed"},{"orgOrder":0,"company":"Amphix Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AMFX-200","moa":"CD29","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Amphix Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amphix Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amphix Bio \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"KJ101","moa":"CD47 | D2 receptor | PD-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Undisclosed"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Dialco Medical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Dialco Medical","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Dialco Medical"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Undisclosed"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Moleac","sponsor":"PT Ferron Par Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SINGAPORE","productType":"Plant Extract\/Herbal","year":"2024","type":"Partnership","leadProduct":"MLC901","moa":"Cholinesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleac \/ PT Ferron Par Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moleac \/ PT Ferron Par Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"D-Panthenol","moa":"CHRM3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pinteon Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Advanced Technology International","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Funding","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pinteon Therapeutics \/ Advanced Technology International","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Advanced Technology International"},{"orgOrder":0,"company":"StemCells, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"HuCNS-SC Cell","moa":"CNS cells","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"StemCells, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCells, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"StemCells, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"StemCells, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"HuCNS-SC Cell","moa":"CNS cells","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"StemCells, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCells, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"StemCells, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Octaplex","moa":"Coagulation factor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Corline Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Renaparin","moa":"Coagulation factor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Corline Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Corline Biomedical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corline Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"David Garcia Cinca","sponsor":"Dr. Juan Carlos Garc\u00eda Pag\u00e1n","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"David Garcia Cinca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David Garcia Cinca \/ Dr. Juan Carlos Garc\u00eda Pag\u00e1n","highestDevelopmentStatusID":"10","companyTruncated":"David Garcia Cinca \/ Dr. Juan Carlos Garc\u00eda Pag\u00e1n"},{"orgOrder":0,"company":"Aegle Therapeutics","sponsor":"Congressionally Directed Medical Research Programs","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AGLE-102","moa":"COL7A1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Aegle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aegle Therapeutics \/ Congressionally Directed Medical Research Programs","highestDevelopmentStatusID":"6","companyTruncated":"Aegle Therapeutics \/ Congressionally Directed Medical Research Programs"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Australian and New Zealand Intensive Care Research Centre","sponsor":"Austin Hospital, Melbourne Australia | Melbourne Health | Barwon Health | Monash Health | The Alfred | Wellington Hospital | Western Health, Australia","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Australian and New Zealand Intensive Care Research Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Australian and New Zealand Intensive Care Research Centre \/ Austin Hospital, Melbourne Australia | Melbourne Health | Barwon Health | Monash Health | The Alfred | Wellington Hospital | Western Health, Australia","highestDevelopmentStatusID":"8","companyTruncated":"Australian and New Zealand Intensive Care Research Centre \/ Austin Hospital, Melbourne Australia | Melbourne Health | Barwon Health | Monash Health | The Alfred | Wellington Hospital | Western Health, Australia"},{"orgOrder":0,"company":"Ceapro","sponsor":"Angiogenesis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oat Beta Glucan","moa":"Collagen synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceapro \/ Angiogenesis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Angiogenesis Foundation"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apellis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"9","companyTruncated":"Alexion Pharmaceuticals \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ReAlta Life Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"anti-inflammatory\/analgesic agents (ibuprofen type)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Allegheny Singer Research Institute","sponsor":"CTM Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Thalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Allegheny Singer Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegheny Singer Research Institute \/ CTM Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Allegheny Singer Research Institute \/ CTM Biomedical"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"CSIRO","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"CTLA-4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Amplia Therapeutics \/ CSIRO"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Western University","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Western University","highestDevelopmentStatusID":"6","companyTruncated":"London Health Sciences Centre \/ Western University"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacoeconomic Unit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Pharmacoeconomic Unit","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacoeconomic Unit \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacoeconomic Unit \/ Undisclosed"},{"orgOrder":0,"company":"Dave Hostler","sponsor":"Federal Emergency Management Administration | Eyemarker Systems","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Dave Hostler","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dave Hostler \/ Federal Emergency Management Administration | Eyemarker Systems","highestDevelopmentStatusID":"1","companyTruncated":"Dave Hostler \/ Federal Emergency Management Administration | Eyemarker Systems"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fidia Farmaceutici Spa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fidia Farmaceutici Spa \/ Undisclosed"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"ClinSearch | CRM Biometrics | Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Teikoku Seiyaku \/ ClinSearch | CRM Biometrics | Clinigen Group","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Seiyaku \/ ClinSearch | CRM Biometrics | Clinigen Group"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Deutsche Sporthochschule K\u00f6ln","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Naproxen","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bayer AG \/ Deutsche Sporthochschule K\u00f6ln","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Deutsche Sporthochschule K\u00f6ln"},{"orgOrder":0,"company":"Gansu Provincial Hospital of Traditional Chinese Medicine (TCM)","sponsor":"Dong-A ST Co., Ltd. | Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aceclofenac","moa":"Cyclooxygenase-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Gansu Provincial Hospital of Traditional Chinese Medicine (TCM)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gansu Provincial Hospital of Traditional Chinese Medicine (TCM) \/ Dong-A ST Co., Ltd. | Seoul National University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Gansu Provincial Hospital of Traditional Chinese Medicine (TCM) \/ Dong-A ST Co., Ltd. | Seoul National University Hospital"},{"orgOrder":0,"company":"NeuroVive Pharmaceutical AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"NeuroVive Pharmaceutical AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NeuroVive Pharmaceutical AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroVive Pharmaceutical AB \/ Undisclosed"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TT301","moa":"Cytokines","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OPKO Health \/ Undisclosed"},{"orgOrder":0,"company":"NanoRay Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"Iodinated Thymidine Analogue","moa":"DNA synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"NanoRay Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanoRay Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NanoRay Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cosmo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"K-PAX Pharmaceuticals","sponsor":"VA Palo Alto Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"K-PAX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"K-PAX Pharmaceuticals \/ VA Palo Alto Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"K-PAX Pharmaceuticals \/ VA Palo Alto Health Care System"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innogene Kalbiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SINGAPORE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hyperosmolar Sodium Lactate","moa":"Electrolyte\/acid-base balance","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Innogene Kalbiotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innogene Kalbiotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innogene Kalbiotech \/ Undisclosed"},{"orgOrder":0,"company":"Noorik Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Noorik Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noorik Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noorik Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Techpool Bio-Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Techpool Bio-Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Techpool Bio-Pharma"},{"orgOrder":0,"company":"Australian and New Zealand Intensive Care Research Centre","sponsor":"University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Australian and New Zealand Intensive Care Research Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Australian and New Zealand Intensive Care Research Centre \/ University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer","highestDevelopmentStatusID":"10","companyTruncated":"Australian and New Zealand Intensive Care Research Centre \/ University College Dublin | Medical Research Institute of New Zealand | Medical Research Future Fund | Health Research Board, Ireland | Health Research Council NZ | Irish Critical Care Clinical Trials Network | ANZICS Clinical Trials Group | Monash Univer"},{"orgOrder":0,"company":"Neurological Associates of West Los Angeles","sponsor":"BioVie","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NE3107","moa":"Estrogen receptor (ESR)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neurological Associates of West Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurological Associates of West Los Angeles \/ BioVie","highestDevelopmentStatusID":"8","companyTruncated":"Neurological Associates of West Los Angeles \/ BioVie"},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Undisclosed"},{"orgOrder":0,"company":"Humanetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Undisclosed"},{"orgOrder":0,"company":"Humanetics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Humanetics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ US Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Humanetics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ US Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanetics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pharmbio Korea","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Lipase","moa":"Fatty acids","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seoul National University Hospital \/ Pharmbio Korea","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Pharmbio Korea"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rigshospitalet \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ CSL Behring"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Fibrinogen Concentrate","moa":"Fibrinogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Humanetics","sponsor":"US Department of Defense | Joint Warfighter Medical Research Program","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BIO300","moa":"Free radical","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ US Department of Defense | Joint Warfighter Medical Research Program","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ US Department of Defense | Joint Warfighter Medical Research Program"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ iOR Partners"},{"orgOrder":0,"company":"Spectrum Health - Lakeland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Magnesium","moa":"GABA-B receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Spectrum Health - Lakeland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectrum Health - Lakeland \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Spectrum Health - Lakeland \/ Undisclosed"},{"orgOrder":0,"company":"AlaMab Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ALMB-0166","moa":"Gap junction alpha-1 protein (GJA1)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"AlaMab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlaMab Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AlaMab Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Novo Nordisk"},{"orgOrder":0,"company":"James J. Peters Veterans Affairs Medical Center","sponsor":"Kessler Institute for Rehabilitation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"James J. Peters Veterans Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation","highestDevelopmentStatusID":"11","companyTruncated":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Novo Nordisk"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"QATAR","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Eastern Ontario","sponsor":"Alberta Children's Hospital | British Columbia Children's Hospital | London Health Sciences Centre | CHU Sainte-Justine | IWK Health Centre | Montreal Children's Hospital of the MUHC","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Children's Hospital of Eastern Ontario","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Children's Hospital of Eastern Ontario \/ Alberta Children's Hospital | British Columbia Children's Hospital | London Health Sciences Centre | CHU Sainte-Justine | IWK Health Centre | Montreal Children's Hospital of the MUHC","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital of Eastern Ontario \/ Alberta Children's Hospital | British Columbia Children's Hospital | London Health Sciences Centre | CHU Sainte-Justine | IWK Health Centre | Montreal Children's Hospital of the MUHC"},{"orgOrder":0,"company":"Jerry Zimmerman","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Children's Hospital of Eastern Ontario","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Jerry Zimmerman","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jerry Zimmerman \/ Gansu Provincial Maternal and Child Health Care Hospital | Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Children's Hospital of Eastern Ontario","highestDevelopmentStatusID":"10","companyTruncated":"Jerry Zimmerman \/ Gansu Provincial Maternal and Child Health Care Hospital | Canadian Institutes of Health Research | Canadian Critical Care Trials Group | Children's Hospital of Eastern Ontario"},{"orgOrder":0,"company":"Rutgers University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rutgers University \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers University \/ Undisclosed"},{"orgOrder":0,"company":"James J. Peters Veterans Affairs Medical Center","sponsor":"Kessler Institute for Rehabilitation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"James J. Peters Veterans Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation","highestDevelopmentStatusID":"6","companyTruncated":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"North Memorial Health Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"North Memorial Health Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North Memorial Health Care \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"North Memorial Health Care \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Undisclosed"},{"orgOrder":0,"company":"SHINKEI Therapeutics, Inc","sponsor":"Duke Clinical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SHINKEI Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHINKEI Therapeutics, Inc \/ Duke Clinical Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"SHINKEI Therapeutics, Inc \/ Duke Clinical Research Institute"},{"orgOrder":0,"company":"Birch BioMed","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CAS 492-27-3","moa":"Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 2A; Aryl hydrocarbon receptor; G-protein coupled receptor 35","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Birch BioMed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"Birch BioMed \/ Nutrasource","highestDevelopmentStatusID":"9","companyTruncated":"Birch BioMed \/ Nutrasource"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Attwill Medical Solutions","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Collaboration","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revive Therapeutics \/ Attwill Medical Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Attwill Medical Solutions"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fezagepras","moa":"G-protein coupled receptor 84 | Free fatty acid receptor 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Liminal BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Center for Neurological Studies","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Center for Neurological Studies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Center for Neurological Studies \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Center for Neurological Studies \/ Novo Nordisk"},{"orgOrder":0,"company":"University of Texas Medical Branch, Galveston","sponsor":"US Department of Defense | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"University of Texas Medical Branch, Galveston","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Medical Branch, Galveston \/ US Department of Defense | Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"University of Texas Medical Branch, Galveston \/ US Department of Defense | Pfizer Inc"},{"orgOrder":0,"company":"MRM Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BELGIUM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MRM Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health \/ Undisclosed"},{"orgOrder":0,"company":"MRM Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BELGIUM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MRM Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Dolcanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dimercaprol","moa":"Heavy metals","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Liverpool School of Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liverpool School of Tropical Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Liverpool School of Tropical Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"University Health Network, Toronto \/ Gilead Sciences"},{"orgOrder":0,"company":"National Institute of Diabetes and Digestive and Kidney Diseases","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Asunaprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"National Institute of Diabetes and Digestive and Kidney Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Diabetes and Digestive and Kidney Diseases \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Diabetes and Digestive and Kidney Diseases \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Florida Atlantic University","sponsor":"Baptist Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Diphenhydramine","moa":"Histamine H1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Florida Atlantic University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Florida Atlantic University \/ Baptist Health","highestDevelopmentStatusID":"10","companyTruncated":"Florida Atlantic University \/ Baptist Health"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Smofkabiven","moa":"Homeostasis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AB Brunna \/ Parexel"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Smofkabiven","moa":"Homeostasis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AB Brunna \/ Parexel"},{"orgOrder":0,"company":"Yuria-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UKRAINE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sodium Lactate","moa":"Homeostasis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Yuria-Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuria-Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuria-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Boston Children's Hospital | Children's Healthcare of Atlanta | Children's Hospital Colorado | Children's Hospital Los Angeles | The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | Children's Hospital and Health System F","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sodium Lactate","moa":"Homeostasis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Children's Hospital of Philadelphia \/ Boston Children's Hospital | Children's Healthcare of Atlanta | Children's Hospital Colorado | Children's Hospital Los Angeles | The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | Children's Hospital and Health System F","highestDevelopmentStatusID":"10","companyTruncated":"Children's Hospital of Philadelphia \/ Boston Children's Hospital | Children's Healthcare of Atlanta | Children's Hospital Colorado | Children's Hospital Los Angeles | The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | Children's Hospital and Health System F"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"NITTO DENKO CORP","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ND-L02-s0201","moa":"HSP47","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ NITTO DENKO CORP","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ NITTO DENKO CORP"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Daprodustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Ointment","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BVS857","moa":"IGF-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Partnership","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ National Institutes of Health"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Undisclosed"},{"orgOrder":0,"company":"Coalition for National Trauma Research","sponsor":"Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pathogen-Reduced Plasma","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Coalition for National Trauma Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coalition for National Trauma Research \/ Cerus Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Coalition for National Trauma Research \/ Cerus Corporation"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"Wuhu City Second People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Shenfu","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ Wuhu City Second People\u2019s Hospital","highestDevelopmentStatusID":"11","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ Wuhu City Second People\u2019s Hospital"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"NASA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Mosedipimod","moa":"immunomodulators","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ NASA","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem Lifesciences Corporation \/ NASA"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"HTX-001","moa":"IncRNA","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"HAYA Therapeutics \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Therapeutics \/ Broadview Ventures"},{"orgOrder":0,"company":"veriNOS operations GmbH","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"veriNOS operations GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"veriNOS operations GmbH \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"veriNOS operations GmbH \/ Icon Plc"},{"orgOrder":0,"company":"veriNOS operations GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"veriNOS operations GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"veriNOS operations GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"veriNOS operations GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vasopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Undisclosed"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vasopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Undisclosed"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vasopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"||Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Atlantic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"Alicaforsen","moa":"Intercellular adhesion molecule-1 mRNA 3'UTR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Atlantic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Enema","sponsorNew":"Atlantic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atlantic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FINLAND","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Tellus Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"TT-20","moa":"Interleukin-12 | Interleukin-23","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tellus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tellus Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Tellus Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Tellus Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series A Financing","leadProduct":"TT-20","moa":"Interleukin-12 | Interleukin-23","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Tellus Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tellus Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Tellus Therapeutics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Eli Lilly"},{"orgOrder":0,"company":"Flavio Vincenti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Flavio Vincenti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flavio Vincenti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Flavio Vincenti \/ Undisclosed"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"McLaren Health Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"McLaren Health Care","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McLaren Health Care \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"McLaren Health Care \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Pharmakea therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"PAT-1251","moa":"Lysyl oxidase homolog 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Pharmakea therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Pharmakea therapeutics"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"AdiSave","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ADSC-SVF-002","moa":"Mesenchymal stem cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"AdiSave","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdiSave \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AdiSave \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"A.A. Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Allo-Ascs","moa":"Mesenchymal stem cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"A.A. Partners","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Suspension","sponsorNew":"A.A. Partners \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"A.A. Partners \/ Undisclosed"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"7","companyTruncated":"Hope Biosciences \/ University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Salud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Salud Pharma"},{"orgOrder":0,"company":"ProgenaCare Global","sponsor":"Kane Biotech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"ProgenaCare Global","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"ProgenaCare Global \/ Kane Biotech","highestDevelopmentStatusID":"15","companyTruncated":"ProgenaCare Global \/ Kane Biotech"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-17299425","moa":"mGluR2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Rennes University Hospital","sponsor":"H.A.C. PHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fludrocortisone Acetate","moa":"Mineralocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Rennes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rennes University Hospital \/ H.A.C. PHARMA","highestDevelopmentStatusID":"9","companyTruncated":"Rennes University Hospital \/ H.A.C. PHARMA"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Kaneka Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Kaneka Corporation"},{"orgOrder":0,"company":"Medasense Biometrics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Remifentanil","moa":"Mu opioid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Medasense Biometrics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medasense Biometrics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medasense Biometrics \/ Undisclosed"},{"orgOrder":0,"company":"James J. Peters Veterans Affairs Medical Center","sponsor":"Kessler Institute for Rehabilitation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"James J. Peters Veterans Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation","highestDevelopmentStatusID":"6","companyTruncated":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Merck & Co"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"University of Minnesota | Thorne HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ University of Minnesota | Thorne HealthTech","highestDevelopmentStatusID":"1","companyTruncated":"Mayo Clinic \/ University of Minnesota | Thorne HealthTech"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Cerebrolysin","moa":"Neurotrophic factor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ever Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ever Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"Ammonia||NF-?B\/NOS2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Ocera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ocera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christiana Care Health Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Christiana Care Health Services \/ Undisclosed"},{"orgOrder":0,"company":"ReNetX Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AXER-204","moa":"Nogo receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"ReNetX Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReNetX Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ReNetX Bio \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"Public Health Service, Murcia | Universidad de Murcia | Hospital Universitario Virgen de la Arrixaca | MurciaSalud","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Amniotic Membrane","moa":"None","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Red de Terapia Celular \/ Public Health Service, Murcia | Universidad de Murcia | Hospital Universitario Virgen de la Arrixaca | MurciaSalud","highestDevelopmentStatusID":"6","companyTruncated":"Red de Terapia Celular \/ Public Health Service, Murcia | Universidad de Murcia | Hospital Universitario Virgen de la Arrixaca | MurciaSalud"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Yoko Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxiracetam","moa":"nootropes (piracetam type)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Nanjing Yoko Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanjing Yoko Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanjing Yoko Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Rehabilitation Hospital of Indiana","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Rehabilitation Hospital of Indiana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rehabilitation Hospital of Indiana \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Rehabilitation Hospital of Indiana \/ Eli Lilly"},{"orgOrder":0,"company":"John Muir Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pseudoephedrine","moa":"Norepinephrine transporter","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"John Muir Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Pill","sponsorNew":"John Muir Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"John Muir Health \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kiniksa Pharmaceuticals","amount2":0.69999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.69999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Kiniksa Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Kiniksa Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Quark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"QPI-1002","moa":"p53 mRNA","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Quark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Quark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-6302","moa":"Pan-LOX","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"Pharmaxis \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaxis \/ Undisclosed"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Escharex","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stealth Biotherapeutics \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Icon Plc"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Sovateltide","moa":"peptides","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Trofinetide","moa":"IGF-1 receptor||peptides: neurologic indications","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuren Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Neuren Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuren Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Trofinetide","moa":"IGF-1 receptor||peptides: neurologic indications","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Neuren Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Neuren Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuren Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Saroglitazar","moa":"Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor alpha","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Miami VA Healthcare System | VA Salt Lake City Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ Miami VA Healthcare System | VA Salt Lake City Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ Miami VA Healthcare System | VA Salt Lake City Health Care System"},{"orgOrder":0,"company":"Ophirex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Varespladib","moa":"Phospholipase A2 group IIA","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ophirex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ophirex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ophirex \/ Undisclosed"},{"orgOrder":0,"company":"Ophirex","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Varespladib Methyl","moa":"Phospholipase A2 group IIA | Group X secretory phospholipase A2 | Phospholipase A2 group V","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ophirex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ophirex \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Ophirex \/ Premier Research Group"},{"orgOrder":0,"company":"Ophirex","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Varespladib Methyl","moa":"Phospholipase A2 group IIA | Group X secretory phospholipase A2 | Phospholipase A2 group V","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ophirex","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.040000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ophirex \/ AXA IM Alts","highestDevelopmentStatusID":"8","companyTruncated":"Ophirex \/ AXA IM Alts"},{"orgOrder":0,"company":"Engelhard Arzneimittel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tyrothricin","moa":"Phospholipid membrane; Acetylcholinesterase; Beta-galactosidase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Engelhard Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engelhard Arzneimittel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Engelhard Arzneimittel \/ Undisclosed"},{"orgOrder":0,"company":"Arava Bio Tech","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Arava Bio Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Arava Bio Tech \/ Cato Research","highestDevelopmentStatusID":"8","companyTruncated":"Arava Bio Tech \/ Cato Research"},{"orgOrder":0,"company":"Arava Bio Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AR101","moa":"PKC-beta","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Arava Bio Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Arava Bio Tech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arava Bio Tech \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Defence Research and Development Canada","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dextrans","moa":"Plasma expander","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Defence Research and Development Canada","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Defence Research and Development Canada"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Netherlands Brain Foundation | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"C1 Esterase Inhibitor","moa":"Plasma protease C1 inhibitor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Netherlands Brain Foundation | Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Leiden University Medical Center \/ Netherlands Brain Foundation | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Bio 54","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BXP154B","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Bio 54","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio 54 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio 54 \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"San Diego Veterans Healthcare System","sponsor":"Inflammagen\/Leading Ventures","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"San Diego Veterans Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"San Diego Veterans Healthcare System \/ Inflammagen\/Leading Ventures","highestDevelopmentStatusID":"8","companyTruncated":"San Diego Veterans Healthcare System \/ Inflammagen\/Leading Ventures"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Physician Services Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ Physician Services Incorporated","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Physician Services Incorporated"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ascension Health \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Heart, Lung, and Blood Institute | U.S. Army Medical Research and Development Command | Canadian Institutes of Health Research | Heart and Stroke Foundation | American Heart Association | Defence Research and Development Canada","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Washington \/ National Heart, Lung, and Blood Institute | U.S. Army Medical Research and Development Command | Canadian Institutes of Health Research | Heart and Stroke Foundation | American Heart Association | Defence Research and Development Canada","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ National Heart, Lung, and Blood Institute | U.S. Army Medical Research and Development Command | Canadian Institutes of Health Research | Heart and Stroke Foundation | American Heart Association | Defence Research and Development Canada"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vapogenix","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Sevoflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta) | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 2 | GABA-A receptor; anion channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Vapogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vapogenix \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Vapogenix \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BIIB093","moa":"Potassium channel\/SUR1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Remedy Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","sponsor":"Servier | KKS Netzwerk","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Martin-Luther-Universit\u00e4t Halle-Wittenberg \/ Servier | KKS Netzwerk","highestDevelopmentStatusID":"8","companyTruncated":"Martin-Luther-Universit\u00e4t Halle-Wittenberg \/ Servier | KKS Netzwerk"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Thinkequity"},{"orgOrder":0,"company":"Oragenics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Avance Clinical"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2025","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2025","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Thinkequity"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Erase PTSD","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Erase PTSD","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Erase PTSD"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Avance Clinical"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Undisclosed"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"University of Kansas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Human Ghrelin","moa":"prehormones or hormone-release stimulating peptides","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Human Ghrelin","moa":"prehormones or hormone-release stimulating peptides","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TCA Cellular Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Autologous Bone Marrow-Derived Mesenchymal Stem Cell","moa":"Progenitor cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"TCA Cellular Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCA Cellular Therapy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TCA Cellular Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Azficel-T","moa":"Progenitor cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Castle Creek Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Castle Creek Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Bone Marrow Concentrate","moa":"Progenitor cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"China Spinal Cord Injury Network","sponsor":"Chengdu PLA General Hospital | StemCyte","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Cord Blood Cell","moa":"Progenitor cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"China Spinal Cord Injury Network","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China Spinal Cord Injury Network \/ Chengdu PLA General Hospital | StemCyte","highestDevelopmentStatusID":"7","companyTruncated":"China Spinal Cord Injury Network \/ Chengdu PLA General Hospital | StemCyte"},{"orgOrder":0,"company":"Pontificia Universidad Catolica de Chile","sponsor":"Hospital del Salvador | SymbiOx Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHILE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Dermal Regeneration Photosynthetic Matrix","moa":"Progenitor cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pontificia Universidad Catolica de Chile","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Pontificia Universidad Catolica de Chile \/ Hospital del Salvador | SymbiOx Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Pontificia Universidad Catolica de Chile \/ Hospital del Salvador | SymbiOx Inc."},{"orgOrder":0,"company":"PolyMedics Innovations","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"PolyMedics Innovations","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"PolyMedics Innovations \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"PolyMedics Innovations \/ MediWound"},{"orgOrder":0,"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Genfa Medica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genfa Medica \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"Genfa Medica \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Funding","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.20999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.20999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Ghassan Aboud Group","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Ghassan Aboud Group"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ US Department of Defense"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vericel Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"||Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vericel Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Balance Medical","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Balance Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Balance Medical \/ MediWound","highestDevelopmentStatusID":"10","companyTruncated":"Balance Medical \/ MediWound"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Misoprostol","moa":"Prostanoid EP3 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Eicos Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Eicos Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eicos Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eicos Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Jakob Stensballe","sponsor":"Innovation Fund Denmark | Independent Research Fund Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Jakob Stensballe","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jakob Stensballe \/ Innovation Fund Denmark | Independent Research Fund Denmark","highestDevelopmentStatusID":"9","companyTruncated":"Jakob Stensballe \/ Innovation Fund Denmark | Independent Research Fund Denmark"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Rhode Island Hospital","sponsor":"University of Rhode Island | United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Rhode Island Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rhode Island Hospital \/ University of Rhode Island | United Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Rhode Island Hospital \/ University of Rhode Island | United Therapeutics"},{"orgOrder":0,"company":"HealOr","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"HO\/03\/03","moa":"Protein kinase C (PRKC)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"HealOr","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HealOr \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HealOr \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Trident Clinical Research Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"KAI-1678","moa":"Protein kinase C epsilon","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Trident Clinical Research Pty Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Trident Clinical Research Pty Ltd"},{"orgOrder":0,"company":"Ischemix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"CMX-2043","moa":"Proto-oncogene c-Met (MET)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ischemix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ischemix \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ischemix \/ US Department of Defense"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"Vivox","sponsor":"NurExone Biologic","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Exosome","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vivox","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivox \/ NurExone Biologic","highestDevelopmentStatusID":"4","companyTruncated":"Vivox \/ NurExone Biologic"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"PTGS1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"NervGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NVG-291","moa":"PTP sigma","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"NervGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NervGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NervGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NervGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NVG-291","moa":"PTP sigma","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"NervGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NervGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NervGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Milan","sponsor":"BMG Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"PTPN1 messenger RNA (PTPN1 mRNA)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"University of Milan \/ BMG Pharma","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ BMG Pharma"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"RUSSIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inosine","moa":"Purine nucleoside phosphorylase; IAG-nucleoside hydrolase; Purine nucleoside phosphorylase DeoD-type","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Neptunus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Polydatin","moa":"Pyruvate kinase PKM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neptunus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neptunus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neptunus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"Repulsive guidance molecule A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"Repulsive guidance molecule A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"Repulsive guidance molecule A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MT-3921","moa":"Repulsive guidance molecule A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MT-3921","moa":"Repulsive guidance molecule A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Cethrin","moa":"Rho-associated protein kinase (ROCK)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"BioAxone BioSciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BioAxone BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cethrin","moa":"Rho-associated protein kinase (ROCK)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"BioAxone BioSciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BioAxone BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BA-1049","moa":"ROCK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAxone BioSciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Simbec Research","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Simbec Research","highestDevelopmentStatusID":"6","companyTruncated":"Redx Pharma \/ Simbec Research"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Oregon Health and Science University \/ Merck & Co"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Merck & Co | University of Texas System | Respiratory Motion, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Merck & Co | University of Texas System | Respiratory Motion, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Merck & Co | University of Texas System | Respiratory Motion, Inc"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"NorthShore University HealthSystem","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Dantrolene","moa":"Ryanodine receptor 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"NorthShore University HealthSystem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dantrolene","moa":"Ryanodine receptor 3 | Ryanodine receptor 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eagle Pharmaceuticals \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Quintiles Inc"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Kessler Institute for Rehabilitation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"VA Office of Research and Development \/ Kessler Institute for Rehabilitation","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ Kessler Institute for Rehabilitation"},{"orgOrder":0,"company":"EicOsis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EicOsis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Life Science Pipeline Inc.","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Buspirone","moa":"Serotonin 1a (5-HT1a) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Nordic Life Science Pipeline Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Life Science Pipeline Inc. \/ US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Life Science Pipeline Inc. \/ US Department of Defense"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Eletriptan Hydrobromide","moa":"Serotonin 1b (5-HT1b) receptor | Serotonin 1f (5-HT1f) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"7","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"NWTraumatherapies","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NWTraumatherapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NWTraumatherapies \/ World Health Organization","highestDevelopmentStatusID":"6","companyTruncated":"NWTraumatherapies \/ World Health Organization"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Wesana Health \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"BMS-986263","moa":"SERPINH1 gene","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"ProTechSure Scientific","sponsor":"Poudre Valley Health System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dimethicone","moa":"Skin barrier","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"ProTechSure Scientific","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"ProTechSure Scientific \/ Poudre Valley Health System","highestDevelopmentStatusID":"7","companyTruncated":"ProTechSure Scientific \/ Poudre Valley Health System"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oleogel-S10","moa":"Skin barrier","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Medline Industries","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Plurogel","moa":"Skin barrier","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"University of Manitoba \/ Medline Industries","highestDevelopmentStatusID":"7","companyTruncated":"University of Manitoba \/ Medline Industries"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"AlloSource","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Skin Allograft","moa":"Skin barrier","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ AlloSource","highestDevelopmentStatusID":"11","companyTruncated":"Virginia Commonwealth University \/ AlloSource"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abalonex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"HONG KONG","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABX-101","moa":"SNAP-25","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Abalonex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abalonex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abalonex \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ UCB Pharma S.A","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Medical Ethics UK","sponsor":"ProTherax | Welsh Wound Innovation Centre","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Medical Ethics UK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Medical Ethics UK \/ ProTherax | Welsh Wound Innovation Centre","highestDevelopmentStatusID":"8","companyTruncated":"Medical Ethics UK \/ ProTherax | Welsh Wound Innovation Centre"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Omeza","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Omeza","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeza \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Omeza \/ Undisclosed"},{"orgOrder":0,"company":"Jeffrey Alan Klein","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Jeffrey Alan Klein","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeffrey Alan Klein \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jeffrey Alan Klein \/ Undisclosed"},{"orgOrder":0,"company":"Orlando Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Orlando Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Orlando Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Orlando Health \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Pacira BioSciences"},{"orgOrder":0,"company":"Orlando Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Orlando Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orlando Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Orlando Health \/ Undisclosed"},{"orgOrder":0,"company":"Andrews Research & Education Foundation","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Andrews Research & Education Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Andrews Research & Education Foundation \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Andrews Research & Education Foundation \/ Pacira BioSciences"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Pacira BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Pacira BioSciences"},{"orgOrder":0,"company":"Chadrick Evans","sponsor":"University of Illinois College of Medicine at Peoria | OSF Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Chadrick Evans","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Chadrick Evans \/ University of Illinois College of Medicine at Peoria | OSF Healthcare System","highestDevelopmentStatusID":"11","companyTruncated":"Chadrick Evans \/ University of Illinois College of Medicine at Peoria | OSF Healthcare System"},{"orgOrder":0,"company":"Kuopio University Hospital","sponsor":"Admescope","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FINLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Levobupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Kuopio University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Kuopio University Hospital \/ Admescope","highestDevelopmentStatusID":"11","companyTruncated":"Kuopio University Hospital \/ Admescope"},{"orgOrder":0,"company":"Yale University","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Chemi SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ITALY","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Chemi SpA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Chemi SpA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chemi SpA \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"U.S. Army Medical Research and Development Command | INTRuST Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedy Pharmaceuticals \/ U.S. Army Medical Research and Development Command | INTRuST Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Remedy Pharmaceuticals \/ U.S. Army Medical Research and Development Command | INTRuST Consortium"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanderbilt University \/ SHIRE PLC","highestDevelopmentStatusID":"11","companyTruncated":"Vanderbilt University \/ SHIRE PLC"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum Toxin Type E","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"T cell surface glycoprotein CD3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"18-F AV-1451","moa":"Tau aggregation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F PI-2620","moa":"Tau aggregation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Walter Reed National Military Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Athersys","sponsor":"The University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"T-cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athersys \/ The University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Athersys \/ The University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"ChitogenX","sponsor":"MCRA","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"ChitogenX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChitogenX \/ MCRA","highestDevelopmentStatusID":"7","companyTruncated":"ChitogenX \/ MCRA"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Health - Lakeland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Thiamine pyrophosphokinase 1; Pyruvate dehydrogenase E1 component","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Spectrum Health - Lakeland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectrum Health - Lakeland \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Spectrum Health - Lakeland \/ Undisclosed"},{"orgOrder":0,"company":"National Cardiovascular Center Harapan Kita Hospital","sponsor":"CRDF Global | Osypka Medical | Dalim BioTech","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDONESIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"National Cardiovascular Center Harapan Kita Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cardiovascular Center Harapan Kita Hospital \/ CRDF Global | Osypka Medical | Dalim BioTech","highestDevelopmentStatusID":"10","companyTruncated":"National Cardiovascular Center Harapan Kita Hospital \/ CRDF Global | Osypka Medical | Dalim BioTech"},{"orgOrder":0,"company":"Thrombotargets Europe S.L","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"TT-173","moa":"Tissue factor (F3)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Thrombotargets Europe S.L","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thrombotargets Europe S.L \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Thrombotargets Europe S.L \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Andexanet Alfa","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ohio State University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Ohio State University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nair, Vinay, D.O.","sponsor":"Icahn School of Medicine at Mount Sinai | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Nair, Vinay, D.O.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nair, Vinay, D.O. \/ Icahn School of Medicine at Mount Sinai | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Nair, Vinay, D.O. \/ Icahn School of Medicine at Mount Sinai | Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Guadalajara","sponsor":"Cell Therapy and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"MEXICO","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University of Guadalajara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Guadalajara \/ Cell Therapy and Technology","highestDevelopmentStatusID":"8","companyTruncated":"University of Guadalajara \/ Cell Therapy and Technology"},{"orgOrder":0,"company":"University of Guadalajara","sponsor":"Cell Therapy and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"MEXICO","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University of Guadalajara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Guadalajara \/ Cell Therapy and Technology","highestDevelopmentStatusID":"8","companyTruncated":"University of Guadalajara \/ Cell Therapy and Technology"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio \/ Department of Defense"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Virginia Commonwealth University","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"Nova Southeastern University","sponsor":"RTI International | Miami VA Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Nova Southeastern University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nova Southeastern University \/ RTI International | Miami VA Healthcare System","highestDevelopmentStatusID":"6","companyTruncated":"Nova Southeastern University \/ RTI International | Miami VA Healthcare System"},{"orgOrder":0,"company":"Opsona Therapeutics Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"OPN-305","moa":"Toll-like receptor 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Opsona Therapeutics Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Opsona Therapeutics Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Opsona Therapeutics Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Statera Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Statera Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Tivic Health Systems","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Statera Biopharma \/ Tivic Health Systems","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ Tivic Health Systems"},{"orgOrder":0,"company":"Scorpius Holdings","sponsor":"Tivic Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Scorpius Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpius Holdings \/ Tivic Health","highestDevelopmentStatusID":"10","companyTruncated":"Scorpius Holdings \/ Tivic Health"},{"orgOrder":0,"company":"Tivic Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Tivic Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tivic Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Tivic Health \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"VX-210","moa":"Transforming protein Rho (RHO)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Roche Diagnostics GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Roche Diagnostics GmbH"},{"orgOrder":0,"company":"Kingman Regional Medical Center","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Kingman Regional Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kingman Regional Medical Center \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Kingman Regional Medical Center \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California, San Francisco \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"University of California, San Francisco \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Northwestern University","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Northwestern University \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"University of New Mexico","sponsor":"La Jolla Pharmaceutical | National Center for Advancing Translational Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of New Mexico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Mexico \/ La Jolla Pharmaceutical | National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of New Mexico \/ La Jolla Pharmaceutical | National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"University of New Mexico","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of New Mexico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Mexico \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of New Mexico \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"APN201","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Apeiron Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Apeiron Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Kringle Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"KP-100IT","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Kringle Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kringle Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kringle Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kringle Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KP-100IT","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Kringle Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kringle Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kringle Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Skingenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"MW-III","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Skingenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skingenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skingenix \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Thrombin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tego Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TPX-114","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Tego Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tego Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tego Science \/ Undisclosed"},{"orgOrder":0,"company":"Tego Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TPX-115","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Tego Science","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tego Science \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tego Science \/ Undisclosed"},{"orgOrder":0,"company":"Tego Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TPX-115","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Tego Science","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tego Science \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tego Science \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation","highestDevelopmentStatusID":"7","companyTruncated":"University of North Carolina \/ OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Lumenis","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Lumenis","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Lumenis"},{"orgOrder":0,"company":"Tikomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dextrans","moa":"TGF-beta||Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tikomed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ Undisclosed"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Funding","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ University of Georgia Research Foundation"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"US Department of Defense | DP Clinical, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AC105","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acorda Therapeutics \/ US Department of Defense | DP Clinical, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Acorda Therapeutics \/ US Department of Defense | DP Clinical, Inc."},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Acellular Human Extracellular Matrix","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Lotion","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.050000000000000003,"dosageForm":"Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ TD Cowen"},{"orgOrder":0,"company":"American CryoStem Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Adipose Derived Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"American CryoStem Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American CryoStem Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"American CryoStem Corporation \/ Undisclosed"},{"orgOrder":0,"company":"InGeneron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Adipose-Derived Regenerative Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"InGeneron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"InGeneron \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InGeneron \/ Undisclosed"},{"orgOrder":0,"company":"InGeneron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Adipose-Derived Regenerative Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"InGeneron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"InGeneron \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InGeneron \/ Undisclosed"},{"orgOrder":0,"company":"Precise Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AdvoGraft One","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Precise Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precise Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Precise Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Ag Tx","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorio Brasileiro de Biologia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Aliviador","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Laboratorio Brasileiro de Biologia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorio Brasileiro de Biologia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorio Brasileiro de Biologia \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Cultured Keratinocytes Dermal Fibroblasts Murine Collagen","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Canadian Institutes of Health Research | Stem Cell Network | Canadian Critical Care Trials Group | Technische Universit\u00e4t Dresden","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord-Derived Human Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ottawa Hospital Research Institute \/ Canadian Institutes of Health Research | Stem Cell Network | Canadian Critical Care Trials Group | Technische Universit\u00e4t Dresden","highestDevelopmentStatusID":"8","companyTruncated":"Ottawa Hospital Research Institute \/ Canadian Institutes of Health Research | Stem Cell Network | Canadian Critical Care Trials Group | Technische Universit\u00e4t Dresden"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Ampakine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Department of Defense"},{"orgOrder":0,"company":"Antria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Antria Cell Preparation","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Antria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antria \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antria \/ Undisclosed"},{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ARGX-117","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"Hospices Civils de Lyon","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Arterial Blood Sampling","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Hospices Civils de Lyon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospices Civils de Lyon \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Hospices Civils de Lyon \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ATYR0101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bukwang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Adipose Tissue Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Bukwang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bukwang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bukwang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Zhejiang Xingyue Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Zhejiang Xingyue Biotechnology Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Zhejiang Xingyue Biotechnology Co., Ltd."},{"orgOrder":0,"company":"McMaster University","sponsor":"Arthrex","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Autologous Conditioned Plasma","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Arthrex","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Arthrex"},{"orgOrder":0,"company":"Amarantus BioScience Holdings","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Engineered Skin Substitute","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Amarantus BioScience Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Amarantus BioScience Holdings \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarantus BioScience Holdings \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous Fresh Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroplast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Undisclosed"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous Fresh Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroplast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Undisclosed"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Lumana Invest","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Fresh Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroplast \/ Lumana Invest","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Lumana Invest"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Hb-Admscs","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Pharmicell Co., Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Pharmicell Co., Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmicell Co., Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pharmicell Co., Inc \/ Undisclosed"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"Castilla y Le\u00f3n Hematology and Hemotherapy Foundation | Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n | Spanish National Health System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Red de Terapia Celular \/ Castilla y Le\u00f3n Hematology and Hemotherapy Foundation | Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n | Spanish National Health System","highestDevelopmentStatusID":"7","companyTruncated":"Red de Terapia Celular \/ Castilla y Le\u00f3n Hematology and Hemotherapy Foundation | Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n | Spanish National Health System"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avita Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Undisclosed"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BE1116","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Birch Bark Extract","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Birch Bark Extract","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"BMP-655\/ACS","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Meabco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BP-C2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meabco \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ Undisclosed"},{"orgOrder":0,"company":"Meabco","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"BP-C2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Meabco \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ National Institutes of Health"},{"orgOrder":0,"company":"Bio 54","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BXP154","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Bio 54","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio 54 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio 54 \/ Undisclosed"},{"orgOrder":0,"company":"Penn State University","sponsor":"MacuHealth | Orlando Regional Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Carotenoid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Penn State University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Penn State University \/ MacuHealth | Orlando Regional Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Penn State University \/ MacuHealth | Orlando Regional Medical Center"},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cerium Oxide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCurity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Regenerative Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"Chitosan-PRP","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Ortho Regenerative Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ortho Regenerative Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ortho Regenerative Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Regenerative Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Chitosan-PRP","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Ortho Regenerative Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ortho Regenerative Technologies \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Ortho Regenerative Technologies \/ Undisclosed"},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"cNP8","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoMatrix Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"cP12","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"NeoMatrix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoMatrix Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"NeoMatrix Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CRIS100","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cultured Epidermal Autograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vericel Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"US Army Medical Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Funding","leadProduct":"Dehydrated Human Amnion Chorion Membrane","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ US Army Medical Research and Development","highestDevelopmentStatusID":"1","companyTruncated":"MiMedx \/ US Army Medical Research and Development"},{"orgOrder":0,"company":"CUTISS AG","sponsor":"RCTs","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DeNovoSkin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CUTISS AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CUTISS AG \/ RCTs","highestDevelopmentStatusID":"10","companyTruncated":"CUTISS AG \/ RCTs"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Dextrose Monohydrate API","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Abigo Medical AB","sponsor":"Essity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Dialkylcarbamoylchloride","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Abigo Medical AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abigo Medical AB \/ Essity","highestDevelopmentStatusID":"15","companyTruncated":"Abigo Medical AB \/ Essity"},{"orgOrder":0,"company":"University of Florida","sponsor":"Iovate Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Dicreatinol Sulfate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Iovate Health Sciences","highestDevelopmentStatusID":"7","companyTruncated":"University of Florida \/ Iovate Health Sciences"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Enzyme","year":"2024","type":"Funding","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Enzyme","year":"2022","type":"Funding","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ US Department of Defense"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DOAC","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Hamilton Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Hamilton Health Sciences"},{"orgOrder":0,"company":"VA Palo Alto Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Dried Plum","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"VA Palo Alto Health Care System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Palo Alto Health Care System \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"VA Palo Alto Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ECP-101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECP Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ECP-101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECP Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CUTISS AG","sponsor":"Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"EHSG","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"CUTISS AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CUTISS AG \/ Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich","highestDevelopmentStatusID":"8","companyTruncated":"CUTISS AG \/ Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich"},{"orgOrder":0,"company":"CUTISS AG","sponsor":"Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"EHSG","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"CUTISS AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CUTISS AG \/ Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich","highestDevelopmentStatusID":"8","companyTruncated":"CUTISS AG \/ Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich"},{"orgOrder":0,"company":"CUTISS AG","sponsor":"Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"EHSG","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"CUTISS AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CUTISS AG \/ Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich","highestDevelopmentStatusID":"8","companyTruncated":"CUTISS AG \/ Wyss Zurich | Julius Clinical | Sintesi Research Srl | University Hospital Z\u00fcrich | University of Zurich"},{"orgOrder":0,"company":"ILYA Pharma","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Emilimogene Sigulactibac","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"ILYA Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ILYA Pharma \/ European Commission","highestDevelopmentStatusID":"8","companyTruncated":"ILYA Pharma \/ European Commission"},{"orgOrder":0,"company":"Eusol Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ES135","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Eusol Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eusol Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eusol Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Akos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"EV102","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Akos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Akos Biosciences"},{"orgOrder":0,"company":"ExeGi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ExeGi \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Histocell","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"FAB117-HC","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Histocell","highestDevelopmentStatusID":"7","companyTruncated":"Ferrer Internacional \/ Histocell"},{"orgOrder":0,"company":"Hunter Holmes Mcguire Veteran Affairs Medical Center","sponsor":"OpenBiome","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hunter Holmes Mcguire Veteran Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ OpenBiome","highestDevelopmentStatusID":"6","companyTruncated":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ OpenBiome"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FSR Peptide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"Northern Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GEM00220","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Northern Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Northern Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northern Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GRNOPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nakhia Impex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"MONGOLIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HA35","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Nakhia Impex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nakhia Impex \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nakhia Impex \/ Undisclosed"},{"orgOrder":0,"company":"Nakhia Impex","sponsor":"Mongolian National University of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"MONGOLIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HA35","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Nakhia Impex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nakhia Impex \/ Mongolian National University of Medical Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Nakhia Impex \/ Mongolian National University of Medical Sciences"},{"orgOrder":0,"company":"LFB Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Hemoleven","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LFB Group \/ Undisclosed"},{"orgOrder":0,"company":"Gregory Gilot","sponsor":"LifeNet Health | Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Human Acellular Dermal Matrix","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Gregory Gilot","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gregory Gilot \/ LifeNet Health | Cleveland Clinic","highestDevelopmentStatusID":"11","companyTruncated":"Gregory Gilot \/ LifeNet Health | Cleveland Clinic"},{"orgOrder":0,"company":"Vaporox","sponsor":"MiMedx","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vaporox","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Vaporox \/ MIMEDX","highestDevelopmentStatusID":"15","companyTruncated":"Vaporox \/ MIMEDX"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Membrane","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Bioinova","sponsor":"University Hospital Motol","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CZECH REPUBLIC","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Human Autologous Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Bioinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioinova \/ University Hospital Motol","highestDevelopmentStatusID":"7","companyTruncated":"Bioinova \/ University Hospital Motol"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"The W. Garfield Weston Foundation | St. Joseph's Health Care London | Parkwood Hospital, London, Ontario","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sachet","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ The W. Garfield Weston Foundation | St. Joseph's Health Care London | Parkwood Hospital, London, Ontario","highestDevelopmentStatusID":"10","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ The W. Garfield Weston Foundation | St. Joseph's Health Care London | Parkwood Hospital, London, Ontario"},{"orgOrder":0,"company":"Neuralstem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Human Spinal Cord Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Neuralstem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neuralstem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuralstem \/ Undisclosed"},{"orgOrder":0,"company":"Translational Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Translational Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Translational Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Essentia Health","sponsor":"University of North Dakota | Dakota Medical Foundation | The Swanson Foundation | State of North Dakota","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hyperbaric Oxygen","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Essentia Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essentia Health \/ University of North Dakota | Dakota Medical Foundation | The Swanson Foundation | State of North Dakota","highestDevelopmentStatusID":"8","companyTruncated":"Essentia Health \/ University of North Dakota | Dakota Medical Foundation | The Swanson Foundation | State of North Dakota"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hyperbaric Oxygen","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intermountain Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Intermountain Health \/ Undisclosed"},{"orgOrder":0,"company":"Intuitive Surgical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"IS-001","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Intuitive Surgical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intuitive Surgical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intuitive Surgical \/ Undisclosed"},{"orgOrder":0,"company":"Anders Perner, MD, PhD","sponsor":"Rigshospitalet | Centre for Research in Intensive Care | Scandinavian Critical Care Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Isotonic Crystalloid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Anders Perner, MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anders Perner, MD, PhD \/ Rigshospitalet | Centre for Research in Intensive Care | Scandinavian Critical Care Trials Group","highestDevelopmentStatusID":"11","companyTruncated":"Anders Perner, MD, PhD \/ Rigshospitalet | Centre for Research in Intensive Care | Scandinavian Critical Care Trials Group"},{"orgOrder":0,"company":"Joben Bio-Medical","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital | Taipei Veterans General Hospital | Efficient Pharma Management","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"TAIWAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"JBM-TC4","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Joben Bio-Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Joben Bio-Medical \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Taipei Veterans General Hospital | Efficient Pharma Management","highestDevelopmentStatusID":"8","companyTruncated":"Joben Bio-Medical \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Taipei Veterans General Hospital | Efficient Pharma Management"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"NSA, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Juice Plus","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Birmingham \/ NSA, Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Birmingham \/ NSA, Inc"},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"KCC2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Axonis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axonis Therapeutics \/ Kerry Murphy","highestDevelopmentStatusID":"2","companyTruncated":"Axonis Therapeutics \/ Kerry Murphy"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"KMRC011","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"iNtRON Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KUC 7483 CL","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"LUT017","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Lutris Pharma","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Lutris Pharma \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Lyophilized Human Placental-based Allograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"French Defence Health Service","sponsor":"Bataillon des marins pompiers de Marseille, France | Military Hospital Laveran,Marseille, France | Samu of Marseille, France | Samu of Lyon, France | Lyon-South Hospital, France | H\u00f4pital Edouard Herriot | Fire Brigade Of Paris Emergency Medicine Dept | C","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lyophilized Plasma","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"French Defence Health Service","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"French Defence Health Service \/ Bataillon des marins pompiers de Marseille, France | Military Hospital Laveran,Marseille, France | Samu of Marseille, France | Samu of Lyon, France | Lyon-South Hospital, France | H\u00f4pital Edouard Herriot | Fire Brigade Of Paris Emergency Medicine Dept | C","highestDevelopmentStatusID":"10","companyTruncated":"French Defence Health Service \/ Bataillon des marins pompiers de Marseille, France | Military Hospital Laveran,Marseille, France | Samu of Marseille, France | Samu of Lyon, France | Lyon-South Hospital, France | H\u00f4pital Edouard Herriot | Fire Brigade Of Paris Emergency Medicine Dept | C"},{"orgOrder":0,"company":"Spectrum Health - Lakeland","sponsor":"Michigan State University","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Magnesium Oxide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Spectrum Health - Lakeland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Health - Lakeland \/ Michigan State University","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Health - Lakeland \/ Michigan State University"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Mepilex AG","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Molnlycke Health Care AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Molnlycke Health Care AB \/ Undisclosed"},{"orgOrder":0,"company":"American CryoStem Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"American CryoStem Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American CryoStem Corporation \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"American CryoStem Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CellTherX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Microsurfaced Skin Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"CellTherX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellTherX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CellTherX \/ Undisclosed"},{"orgOrder":0,"company":"Synedgen","sponsor":"JWMRP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"MIIST305","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synedgen \/ JWMRP","highestDevelopmentStatusID":"4","companyTruncated":"Synedgen \/ JWMRP"},{"orgOrder":0,"company":"Synedgen","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"MIIST305","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Synedgen","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Synedgen \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Synedgen \/ BARDA"},{"orgOrder":0,"company":"Sangart","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MP4OX","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Sangart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sangart \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sangart \/ Undisclosed"},{"orgOrder":0,"company":"Sangart","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"MP4OX","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Sangart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sangart \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sangart \/ Undisclosed"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Memorial Hermann Hospital | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Memorial Hermann Hospital | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ Memorial Hermann Hospital | US Department of Defense"},{"orgOrder":0,"company":"Amen Clinics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Multivitamin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Amen Clinics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amen Clinics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Amen Clinics \/ Undisclosed"},{"orgOrder":0,"company":"S.Biomedics","sponsor":"Linical | Yonsei University","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Neural Precursor Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"S.Biomedics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.Biomedics \/ Linical | Yonsei University","highestDevelopmentStatusID":"7","companyTruncated":"S.Biomedics \/ Linical | Yonsei University"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Neuro Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuroplast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Undisclosed"},{"orgOrder":0,"company":"Moleac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SINGAPORE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Neuroaid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleac \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Moleac \/ Undisclosed"},{"orgOrder":0,"company":"Moleac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SINGAPORE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Neuroaid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moleac \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Neurosteroid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oragenics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Undisclosed"},{"orgOrder":0,"company":"NovaGo Therapeutics ","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NG004","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NovaGo Therapeutics ","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NovaGo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NovaGo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TELA Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nivis Fibrillar Collagen Pack","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"TELA Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TELA Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TELA Bio \/ Undisclosed"},{"orgOrder":0,"company":"Loughborough University","sponsor":"McMaster University | Danone Nutricia Research","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nmes","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Loughborough University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loughborough University \/ McMaster University | Danone Nutricia Research","highestDevelopmentStatusID":"1","companyTruncated":"Loughborough University \/ McMaster University | Danone Nutricia Research"},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NMT-cP12","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NeoMatrix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"KCI USA, Inc","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NPWTi-d","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"KCI USA, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"KCI USA, Inc \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"KCI USA, Inc \/ 3M Company"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Stem Cell Therapeutics Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"NTx 265","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Stem Cell Therapeutics Corp.","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ Stem Cell Therapeutics Corp."},{"orgOrder":0,"company":"Augusta University","sponsor":"NuTech Medical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"Nucel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Augusta University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augusta University \/ NuTech Medical","highestDevelopmentStatusID":"11","companyTruncated":"Augusta University \/ NuTech Medical"},{"orgOrder":0,"company":"Duke University","sponsor":"US Department of Defense | Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ US Department of Defense | Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ US Department of Defense | Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Octapharma | University of Iceland","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Octaplas LG","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rigshospitalet \/ Octapharma | University of Iceland","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ Octapharma | University of Iceland"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurgain Technologies","sponsor":"Lineagen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Agreement","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Neurgain Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurgain Technologies \/ Lineagen","highestDevelopmentStatusID":"7","companyTruncated":"Neurgain Technologies \/ Lineagen"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Oryz-Aspergillus Enzyme","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Kangzhe Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Kangzhe Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Abliva","sponsor":"Owl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"OWL-1410","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Owl Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Abliva \/ Owl Therapeutics"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Pathogen Reduced Lyophilized Cryoprecipitate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Cerus Corporation","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ US Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Cerus Corporation \/ US Department of Defense"},{"orgOrder":0,"company":"Jason Sperry","sponsor":"University of Texas System | University of Louisville | Vanderbilt University | Case Western Reserve University | The University of Tennessee, Knoxville | JPS Health Network | The Methodist Hospital Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Plasma","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Jason Sperry","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jason Sperry \/ University of Texas System | University of Louisville | Vanderbilt University | Case Western Reserve University | The University of Tennessee, Knoxville | JPS Health Network | The Methodist Hospital Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"Jason Sperry \/ University of Texas System | University of Louisville | Vanderbilt University | Case Western Reserve University | The University of Tennessee, Knoxville | JPS Health Network | The Methodist Hospital Research Institute"},{"orgOrder":0,"company":"Chang, Steve S., M.D.","sponsor":"Santa Barbara Cottage Hospital | Accumetrics","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Platelets","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Chang, Steve S., M.D.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chang, Steve S., M.D. \/ Santa Barbara Cottage Hospital | Accumetrics","highestDevelopmentStatusID":"1","companyTruncated":"Chang, Steve S., M.D. \/ Santa Barbara Cottage Hospital | Accumetrics"},{"orgOrder":0,"company":"Primoris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PMS-101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Primoris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primoris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Primoris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"Physician Services Incorporated | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Pill","sponsorNew":"The Hospital for Sick Children \/ Physician Services Incorporated | Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"The Hospital for Sick Children \/ Physician Services Incorporated | Merck & Co"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"R475","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Original BioMedicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"Radprotect","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Original BioMedicals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Original BioMedicals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Original BioMedicals \/ Undisclosed"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RBT-1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Joseph M. Still Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Realskin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"XenoTherapeutics \/ Joseph M. Still Research Foundation","highestDevelopmentStatusID":"10","companyTruncated":"XenoTherapeutics \/ Joseph M. Still Research Foundation"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Massachusetts General Hospital | Joseph M. Still Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Realskin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XenoTherapeutics \/ Massachusetts General Hospital | Joseph M. Still Research Foundation","highestDevelopmentStatusID":"7","companyTruncated":"XenoTherapeutics \/ Massachusetts General Hospital | Joseph M. Still Research Foundation"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Children's National Research Institute | LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Antithrombin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical College of Wisconsin \/ Children's National Research Institute | LFB Group","highestDevelopmentStatusID":"6","companyTruncated":"Medical College of Wisconsin \/ Children's National Research Institute | LFB Group"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Shanghai Jiaotong University School of Medicine | Beijing Children's Hospital | Third Military Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Human GM-CSF","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai Jiaotong University School of Medicine | Beijing Children's Hospital | Third Military Medical University","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai Jiaotong University School of Medicine | Beijing Children's Hospital | Third Military Medical University"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Vanderbilt University Medical Center \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avita Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avita Medical \/ Undisclosed"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avita Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Octapharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ringer-acetat","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Octapharma","highestDevelopmentStatusID":"11","companyTruncated":"Rigshospitalet \/ Octapharma"},{"orgOrder":0,"company":"Regenera Pharma","sponsor":"TransCom Global Ltd. (CRO)","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"RPh201","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Regenera Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenera Pharma \/ TransCom Global Ltd. (CRO)","highestDevelopmentStatusID":"7","companyTruncated":"Regenera Pharma \/ TransCom Global Ltd. (CRO)"},{"orgOrder":0,"company":"Regenera Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"RPh201","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Regenera Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenera Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regenera Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biomedizinische Forschungs","sponsor":"Medical University of Vienna","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"rTSST-1 Variant Vaccine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Biomedizinische Forschungs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomedizinische Forschungs \/ Medical University of Vienna","highestDevelopmentStatusID":"8","companyTruncated":"Biomedizinische Forschungs \/ Medical University of Vienna"},{"orgOrder":0,"company":"Biomedizinische Forschungs","sponsor":"Medical University of Vienna","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"rTSST-1 Variant Vaccine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Biomedizinische Forschungs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomedizinische Forschungs \/ Medical University of Vienna","highestDevelopmentStatusID":"8","companyTruncated":"Biomedizinische Forschungs \/ Medical University of Vienna"},{"orgOrder":0,"company":"Biomedizinische Forschungs","sponsor":"Medical University of Vienna","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"rTSST-1 Variant Vaccine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Biomedizinische Forschungs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomedizinische Forschungs \/ Medical University of Vienna","highestDevelopmentStatusID":"8","companyTruncated":"Biomedizinische Forschungs \/ Medical University of Vienna"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Chrysalis BioTherapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Chrysalis BioTherapeutics \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Chrysalis BioTherapeutics \/ BARDA"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chrysalis BioTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Chrysalis BioTherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Scandinavian Critical Care Trials Group","sponsor":"Copenhagen Trial Unit, Center for Clinical Intervention Research | Rigshospitalet | University of Copenhagen","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Scandinavian Critical Care Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandinavian Critical Care Trials Group \/ Copenhagen Trial Unit, Center for Clinical Intervention Research | Rigshospitalet | University of Copenhagen","highestDevelopmentStatusID":"10","companyTruncated":"Scandinavian Critical Care Trials Group \/ Copenhagen Trial Unit, Center for Clinical Intervention Research | Rigshospitalet | University of Copenhagen"},{"orgOrder":0,"company":"SanBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"SB623 Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Undisclosed"},{"orgOrder":0,"company":"Boston Medical Center","sponsor":"Entera Health, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"SBI","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Boston Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Medical Center \/ Entera Health, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Boston Medical Center \/ Entera Health, Inc"},{"orgOrder":0,"company":"SERDA bv","sponsor":"Metis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SN514-066b","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"SERDA bv","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SERDA bv \/ Metis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"SERDA bv \/ Metis Foundation"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Sodermix Dismutase","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Stratagraft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Stratpharma AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Strataxrt","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Stratpharma AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Stratpharma AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Stratpharma AG \/ Undisclosed"},{"orgOrder":0,"company":"Yonsei University","sponsor":"Stand Up Therapeutics INC.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"STUP-001","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Yonsei University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yonsei University \/ Stand Up Therapeutics INC.","highestDevelopmentStatusID":"7","companyTruncated":"Yonsei University \/ Stand Up Therapeutics INC."},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Stand Up Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"STUP-001","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectorBuilder \/ Stand Up Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VectorBuilder \/ Stand Up Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SUN13837","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"St. Louis University","sponsor":"Next Science","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Surgx Wound Gel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"St. Louis University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"St. Louis University \/ Next Science","highestDevelopmentStatusID":"11","companyTruncated":"St. Louis University \/ Next Science"},{"orgOrder":0,"company":"Synedgen","sponsor":"LSU Health Sciences Center New Orleans","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Synedgen \/ LSU Health Sciences Center New Orleans","highestDevelopmentStatusID":"1","companyTruncated":"Synedgen \/ LSU Health Sciences Center New Orleans"},{"orgOrder":0,"company":"National Cardiovascular Center Harapan Kita Hospital","sponsor":"CRDF Global | Osypka Medical | Dalim BioTech","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDONESIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tetronine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"National Cardiovascular Center Harapan Kita Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cardiovascular Center Harapan Kita Hospital \/ CRDF Global | Osypka Medical | Dalim BioTech","highestDevelopmentStatusID":"10","companyTruncated":"National Cardiovascular Center Harapan Kita Hospital \/ CRDF Global | Osypka Medical | Dalim BioTech"},{"orgOrder":0,"company":"AdventHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tisseel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AdventHealth","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdventHealth \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AdventHealth \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Healiva","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Healiva"},{"orgOrder":0,"company":"RenovaCare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Tissue-Specific Pluripotent Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RenovaCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"RenovaCare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RenovaCare \/ Undisclosed"},{"orgOrder":0,"company":"BioMendics, LLC","sponsor":"Symbio, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Tolasure","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioMendics, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioMendics, LLC \/ Symbio, LLC","highestDevelopmentStatusID":"8","companyTruncated":"BioMendics, LLC \/ Symbio, LLC"},{"orgOrder":0,"company":"BioMendics, LLC","sponsor":"University of Miami","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Tolasure","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioMendics, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioMendics, LLC \/ University of Miami","highestDevelopmentStatusID":"8","companyTruncated":"BioMendics, LLC \/ University of Miami"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Tri-Ax","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halberd Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Halberd Corporation \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"iCoat Medical","sponsor":"CTC Clinical Trial Consultants | Region Skane","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TUM012","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"iCoat Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"iCoat Medical \/ CTC Clinical Trial Consultants | Region Skane","highestDevelopmentStatusID":"7","companyTruncated":"iCoat Medical \/ CTC Clinical Trial Consultants | Region Skane"},{"orgOrder":0,"company":"StemCyte","sponsor":"StemCyte","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Umbilical Cord Blood Mononuclear Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCyte \/ StemCyte","highestDevelopmentStatusID":"8","companyTruncated":"StemCyte \/ StemCyte"},{"orgOrder":0,"company":"SanBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Undisclosed"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vivacelle Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivacelle Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vivacelle Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vivacelle Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivacelle Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vivacelle Bio \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Volulyte","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Veteran Affairs Canada | Ornge | Canadian Blood Services | Sunnybrook Health Sciences Centre | Hamilton Health Sciences | London Health Sciences Centre | Kingston Health Sciences Centre | Health Sciences North","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Whole Blood","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Veteran Affairs Canada | Ornge | Canadian Blood Services | Sunnybrook Health Sciences Centre | Hamilton Health Sciences | London Health Sciences Centre | Kingston Health Sciences Centre | Health Sciences North","highestDevelopmentStatusID":"1","companyTruncated":"Unity Health Toronto \/ Veteran Affairs Canada | Ornge | Canadian Blood Services | Sunnybrook Health Sciences Centre | Hamilton Health Sciences | London Health Sciences Centre | Kingston Health Sciences Centre | Health Sciences North"},{"orgOrder":0,"company":"Banc de Sang i Teixits","sponsor":"Hospital de Neurorehabilitaci\u00f3 Institut Guttmann | Recerca Cl\u00ednica | Syntax for Science, S.L","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"XCEL-UMC-BETA","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Banc de Sang i Teixits","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Banc de Sang i Teixits \/ Hospital de Neurorehabilitaci\u00f3 Institut Guttmann | Recerca Cl\u00ednica | Syntax for Science, S.L","highestDevelopmentStatusID":"7","companyTruncated":"Banc de Sang i Teixits \/ Hospital de Neurorehabilitaci\u00f3 Institut Guttmann | Recerca Cl\u00ednica | Syntax for Science, S.L"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Xeno-Skin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XenoTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XenoTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Third Affiliated Hospital, Sun Yat-sen University","sponsor":"Xellsmart","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"XS228","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Third Affiliated Hospital, Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Third Affiliated Hospital, Sun Yat-sen University \/ Xellsmart","highestDevelopmentStatusID":"8","companyTruncated":"Third Affiliated Hospital, Sun Yat-sen University \/ Xellsmart"},{"orgOrder":0,"company":"Third Affiliated Hospital, Sun Yat-sen University","sponsor":"Xellsmart","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"XS228","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Third Affiliated Hospital, Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Third Affiliated Hospital, Sun Yat-sen University \/ Xellsmart","highestDevelopmentStatusID":"8","companyTruncated":"Third Affiliated Hospital, Sun Yat-sen University \/ Xellsmart"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zifogaptide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xequel Bio \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Xequel Bio \/ US Department of Defense"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Kalinga Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Carbohydrate","year":"2023","type":"Agreement","leadProduct":"Crosslinked Hydrogel","moa":"||Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supriya Lifescience \/ Kalinga Institute of Technology","highestDevelopmentStatusID":"4","companyTruncated":"Supriya Lifescience \/ Kalinga Institute of Technology"},{"orgOrder":0,"company":"iCoat Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"iCM012","moa":"Unknown","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"iCoat Medical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"iCoat Medical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"iCoat Medical \/ Undisclosed"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocelot Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Atlantic Research Group | U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Atlantic Research Group | U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Atlantic Research Group | U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Humacyte","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0.16,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Oberland Capital Management"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Implant","sponsorNew":"Humacyte \/ EF Hutton","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ EF Hutton"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ TD Cowen"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hospital for Special Surgery, New York","sponsor":"Angiocrine Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"E-CEL UVEC","moa":"Vascular endothelium","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hospital for Special Surgery, New York","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Hospital for Special Surgery, New York \/ Angiocrine Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Hospital for Special Surgery, New York \/ Angiocrine Bioscience"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"University of Utah","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intermountain Health \/ University of Utah","highestDevelopmentStatusID":"11","companyTruncated":"Intermountain Health \/ University of Utah"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"FE 202158","moa":"Vasopressin V1a receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Selepressin","moa":"Vasopressin V1a receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hunter Holmes Mcguire Veteran Affairs Medical Center","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Hunter Holmes Mcguire Veteran Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ Otsuka Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Hunter Holmes Mcguire Veteran Affairs Medical Center \/ Otsuka Holdings"},{"orgOrder":0,"company":"First Affiliated Hospital, Sun Yat-Sen University","sponsor":"Guangdong Department of Science and Technology | Second Affiliated Hospital, Sun Yat-sen University | Sixth Affiliated Hospital, Sun Yat-sen University | Chinese PLA General Hospital | Beijing 302 Hospital | Shanghai Changzheng Hospital | Wuhan Union Hosp","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin V2 receptor | Vasopressin V1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"First Affiliated Hospital, Sun Yat-Sen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"First Affiliated Hospital, Sun Yat-Sen University \/ Guangdong Department of Science and Technology | Second Affiliated Hospital, Sun Yat-sen University | Sixth Affiliated Hospital, Sun Yat-sen University | Chinese PLA General Hospital | Beijing 302 Hospital | Shanghai Changzheng Hospital | Wuhan Union Hosp","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital, Sun Yat-Sen University \/ Guangdong Department of Science and Technology | Second Affiliated Hospital, Sun Yat-sen University | Sixth Affiliated Hospital, Sun Yat-sen University | Chinese PLA General Hospital | Beijing 302 Hospital | Shanghai Changzheng Hospital | Wuhan Union Hosp"},{"orgOrder":0,"company":"BioVie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin V2 receptor | Vasopressin V1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVie \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Undisclosed"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Crotalidae Immune Fab","moa":"Venom toxin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Virginia Commonwealth University | NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ Virginia Commonwealth University | NYU Langone Health","highestDevelopmentStatusID":"9","companyTruncated":"VA Office of Research and Development \/ Virginia Commonwealth University | NYU Langone Health"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Hamilton Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Hamilton Health Sciences"},{"orgOrder":0,"company":"University at Albany","sponsor":"US Department of Defense | The Sage Colleges | Women's College Hospital | Severna Park Health and Wellness Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Niacin","moa":"VLDL\/LDL synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University at Albany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oil","sponsorNew":"University at Albany \/ US Department of Defense | The Sage Colleges | Women's College Hospital | Severna Park Health and Wellness Center","highestDevelopmentStatusID":"8","companyTruncated":"University at Albany \/ US Department of Defense | The Sage Colleges | Women's College Hospital | Severna Park Health and Wellness Center"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ Viatris","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ Viatris"},{"orgOrder":0,"company":"Kessler Foundation","sponsor":"National Institute on Disability, Independent Living, and Rehabilitation Research | Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fampridine","moa":"Voltage-gated potassium channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Kessler Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kessler Foundation \/ National Institute on Disability, Independent Living, and Rehabilitation Research | Acorda Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Kessler Foundation \/ National Institute on Disability, Independent Living, and Rehabilitation Research | Acorda Therapeutics"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fampridine","moa":"Voltage-gated potassium channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acorda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acorda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Zhejiang Xingyue Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Zhejiang Xingyue Biotechnology Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Zhejiang Xingyue Biotechnology Co., Ltd."},{"orgOrder":0,"company":"Kunming Tongren Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Kunming Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kunming Tongren Hospital \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kunming Tongren Hospital \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Quintiles Inc | Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Patch","sponsorNew":"Daiichi Sankyo \/ Quintiles Inc | Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Quintiles Inc | Daiichi Sankyo"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Oncodesign Services","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Tiumbio \/ Oncodesign"},{"orgOrder":0,"company":"Direction Centrale du Service de Sant\u00e9 des Arm\u00e9es","sponsor":"TIMC-IMAG | Floralis","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Direction Centrale du Service de Sant\u00e9 des Arm\u00e9es","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Direction Centrale du Service de Sant\u00e9 des Arm\u00e9es \/ TIMC-IMAG | Floralis","highestDevelopmentStatusID":"10","companyTruncated":"Direction Centrale du Service de Sant\u00e9 des Arm\u00e9es \/ TIMC-IMAG | Floralis"},{"orgOrder":0,"company":"Hospices Civils de Lyon","sponsor":"Bioaster | Biomerieux | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Hospices Civils de Lyon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospices Civils de Lyon \/ Bioaster | Biomerieux | Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Hospices Civils de Lyon \/ Bioaster | Biomerieux | Sanofi"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Diagnostica Stago","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Central Hospital, Nancy, France \/ Diagnostica Stago","highestDevelopmentStatusID":"1","companyTruncated":"Central Hospital, Nancy, France \/ Diagnostica Stago"},{"orgOrder":0,"company":"Centre Fran\u00e7ois Baclesse","sponsor":"Inotrem","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Centre Fran\u00e7ois Baclesse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Fran\u00e7ois Baclesse \/ Inotrem","highestDevelopmentStatusID":"1","companyTruncated":"Centre Fran\u00e7ois Baclesse \/ Inotrem"},{"orgOrder":0,"company":"UMC Utrecht","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"UMC Utrecht","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMC Utrecht \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"UMC Utrecht \/ ZonMw"},{"orgOrder":0,"company":"University Hospital, Basel","sponsor":"Marine Polymer Technologies, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"University Hospital, Basel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"University Hospital, Basel \/ Marine Polymer Technologies, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"University Hospital, Basel \/ Marine Polymer Technologies, Inc."},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Relation Therapeutics","amount2":0.31,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.31,"dosageForm":"Undisclosed","sponsorNew":"Relation Therapeutics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Relation Therapeutics \/ GSK"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Recursion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Recursion Pharma"},{"orgOrder":0,"company":"Juvenescence","sponsor":"M42","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Juvenescence","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juvenescence \/ M42","highestDevelopmentStatusID":"6","companyTruncated":"Juvenescence \/ M42"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Surrozen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Surrozen","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Surrozen"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"SINTEF","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argent BioPharma \/ SINTEF","highestDevelopmentStatusID":"4","companyTruncated":"Argent BioPharma \/ SINTEF"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Israeli Shekels","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Israeli Shekels","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Israeli Shekels"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inteligex","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Inteligex","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inteligex"},{"orgOrder":0,"company":"Applied Biologics, LLC","sponsor":"Fondren Orthopedic Group L.L.P. | Texas Orthopedic Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Applied Biologics, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biologics, LLC \/ Fondren Orthopedic Group L.L.P. | Texas Orthopedic Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biologics, LLC \/ Fondren Orthopedic Group L.L.P. | Texas Orthopedic Hospital"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Cook County Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Cook County Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ Cook County Health"},{"orgOrder":0,"company":"WellSpan Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"WellSpan Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WellSpan Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"WellSpan Health \/ Undisclosed"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Albert Einstein Healthcare Network \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"US Department of Defense | National Heart, Lung, and Blood Institute | Resuscitation Outcomes Consortium | Defence Research and Development Canada","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at Houston \/ US Department of Defense | National Heart, Lung, and Blood Institute | Resuscitation Outcomes Consortium | Defence Research and Development Canada","highestDevelopmentStatusID":"10","companyTruncated":"University of Texas Health Science Center at Houston \/ US Department of Defense | National Heart, Lung, and Blood Institute | Resuscitation Outcomes Consortium | Defence Research and Development Canada"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Corporation \/ Mississippi State University"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Avita Medical \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"NeurAegis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeurAegis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeurAegis \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NeurAegis \/ Undisclosed"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuMentis Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"EuMentis Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Distributed Bio","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Distributed Bio","highestDevelopmentStatusID":"4","companyTruncated":"Mediar Therapeutics \/ Distributed Bio"},{"orgOrder":0,"company":"Safi Biosolutions","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Safi Biosolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Safi Biosolutions \/ iBio","highestDevelopmentStatusID":"1","companyTruncated":"Safi Biosolutions \/ iBio"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Corporation \/ Mississippi State University"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mediar Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Mediar Therapeutics \/ Novartis Venture Fund"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"InGeneron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"InGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InGeneron \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"InGeneron \/ Undisclosed"},{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Exalys Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Exalys Therapeutics \/ Catalys Pacific","highestDevelopmentStatusID":"1","companyTruncated":"Exalys Therapeutics \/ Catalys Pacific"},{"orgOrder":0,"company":"Bio-medical Carbon Technology Co., Ltd.","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Bio-medical Carbon Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Bio-medical Carbon Technology Co., Ltd. \/ National Taiwan University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Bio-medical Carbon Technology Co., Ltd. \/ National Taiwan University Hospital"},{"orgOrder":0,"company":"Bio-medical Carbon Technology Co., Ltd.","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Bio-medical Carbon Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Bio-medical Carbon Technology Co., Ltd. \/ National Taiwan University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Bio-medical Carbon Technology Co., Ltd. \/ National Taiwan University Hospital"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Funding","leadProduct":"Foralumab","moa":"T cell surface glycoprotein CD3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tiziana Life Sciences \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Department of Defense"},{"orgOrder":0,"company":"Kensana Health","sponsor":"GEM Global Yield","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2025","type":"Financing","leadProduct":"KV23a","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Kensana Health","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Kensana Health \/ GEM Global Yield","highestDevelopmentStatusID":"8","companyTruncated":"Kensana Health \/ GEM Global Yield"},{"orgOrder":0,"company":"Pontificia Universidad Catolica de Chile","sponsor":"Hospital del Trabajador de Santiago | SymbiOx Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHILE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Pontificia Universidad Catolica de Chile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Pontificia Universidad Catolica de Chile \/ Hospital del Trabajador de Santiago | SymbiOx Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Pontificia Universidad Catolica de Chile \/ Hospital del Trabajador de Santiago | SymbiOx Inc."},{"orgOrder":0,"company":"BILIX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BX-001N","moa":"Bacteria microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BILIX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"BILIX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BILIX \/ Undisclosed"},{"orgOrder":0,"company":"Graegis Pharmaceuticals Ltd","sponsor":"Excelya","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"GR1014","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Graegis Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Graegis Pharmaceuticals Ltd \/ Excelya","highestDevelopmentStatusID":"8","companyTruncated":"Graegis Pharmaceuticals Ltd \/ Excelya"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Peter Heeger","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Peter Heeger","highestDevelopmentStatusID":"9","companyTruncated":"Alexion Pharmaceuticals \/ Peter Heeger"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Daniel Dante Yeh","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Teduglutide","moa":"Glucagon-like peptide 2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Daniel Dante Yeh","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Daniel Dante Yeh"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Mount Sinai St. Luke\u2019s and Mount Sinai West","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Mount Sinai St. Luke\u2019s and Mount Sinai West","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Mount Sinai St. Luke\u2019s and Mount Sinai West"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Steven Orebaugh","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Steven Orebaugh","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Steven Orebaugh"},{"orgOrder":0,"company":"Prothya Biosolutions","sponsor":"UMC Utrecht","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"C1-esterase Inhibitor","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Prothya Biosolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothya Biosolutions \/ UMC Utrecht","highestDevelopmentStatusID":"10","companyTruncated":"Prothya Biosolutions \/ UMC Utrecht"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Patricia Bloom","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Patricia Bloom","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Biosciences \/ Patricia Bloom"},{"orgOrder":0,"company":"Vitruvian Medical Devices, Inc.","sponsor":"Hobart W. Harris","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zinc Oxide","moa":"Zinc","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Vitruvian Medical Devices, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Vitruvian Medical Devices, Inc. \/ Hobart W. Harris","highestDevelopmentStatusID":"7","companyTruncated":"Vitruvian Medical Devices, Inc. \/ Hobart W. Harris"},{"orgOrder":0,"company":"Synedgen","sponsor":"J. Peter Rubin, MD","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Synedgen \/ J. Peter Rubin, MD","highestDevelopmentStatusID":"11","companyTruncated":"Synedgen \/ J. Peter Rubin, MD"},{"orgOrder":0,"company":"BirchBioMed","sponsor":"Bionexus Gene Lab","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"DTXCID5040675","moa":"GPR35","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"BirchBioMed","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"BirchBioMed \/ BioNexus Gene Lab","highestDevelopmentStatusID":"9","companyTruncated":"BirchBioMed \/ BioNexus Gene Lab"},{"orgOrder":0,"company":"Tego Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"TPX-115","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Tego Science","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tego Science \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Tego Science \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Supriya Lifescience

                            India
                            CPhI India
                            Booth #1.B12 & 1.B20
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

                            Lead Product(s) : Undisclosed,Crosslinked Hydrogel

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Kalinga Institute of Technology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Supriya Lifescience Signs Agreement with KIT for Further Development of Wound Healing Gel

                            Details : Through the agreement, Supriya Lifescience will focus on the advancement of GelHeal, a protein-based crosslinked Hydrogel, gel-based cream, which is being evaluated for the treatment of deep wounds.

                            Product Name : GelHeal

                            Product Type : Carbohydrate

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Undisclosed,Crosslinked Hydrogel

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Kalinga Institute of Technology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Supriya

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bloomage Biotechnology Corp., Ltd

                            China
                            CPhI India
                            Booth #RH.L04
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Lumenis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lumenis and Bloomage Biotech jointly released a new product - M22 medical wound dressing

                            Details : M22 medical wound dressing (sodium hyaluronate) is a versatile laser treatment system based on Lumenis' medical beauty concept of "30% Laser Treatment and 70% Postoperative care.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Lumenis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Bloomage Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vectura Ltd

                            United Kingdom
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Incannex Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Trauma...

                            Details : Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicolog...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Incannex Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Skyepharma Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Receives Orphan Drug and Fast Track Designations from the U.S FDA for Elezanumab for the Treatment of S...

                            Details : Elezanumab is a monoclonal antibody of the human immunoglobulin (Ig)G1 isotype that binds selectively to repulsive guidance molecule A (RGMa). Elezanumab is being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity...

                            Details : Elezanumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 04, 2020

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AbbVie Inc

                            U.S.A
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Elezanumab

                            Details : Elezanumab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 20, 2020

                            Lead Product(s) : Elezanumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Atlantic Pharmaceuticals

                            Country
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alicaforsen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

                            Details : Alicaforsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pouchitis.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 17, 2015

                            Lead Product(s) : Alicaforsen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ever Pharma

                            Austria
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

                            Lead Product(s) : Cerebrolysin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery

                            Details : Cerebrolysin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Injuries, Traumatic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 25, 2012

                            Lead Product(s) : Cerebrolysin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Ever Pharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tiziana Life Sciences

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tiziana Life Sciences

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Department of Defense Awards Grant to Advance Tiziana Intranasal Anti-CD3 Therapy

                            Details : The DoD award will support a three-year study of intranasal anti-CD3, foralumab, in the acute phase of spinal cord injury.

                            Product Name : TZLS-401

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 15, 2025

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pontificia Universidad Catolica de Chile

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pontificia Universidad Catolica de Chile

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Hospital del Trabajador de Santiago | SymbiOx Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of a Photosynthetic Dermal Matrix for the Treatment of Full-Thickness Skin Wounds

                            Details : This drug candidate is currently being evaluated in Phase II clinical studies for the treatment of Wounds and Injuries.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 05, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Hospital del Trabajador de Santiago | SymbiOx Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth